Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for AC Immune (ACIU) over the last 11 years, with Q3 2025 value amounting to -$72504.3.

  • AC Immune's Capital Expenditures rose 6282.99% to -$72504.3 in Q3 2025 from the same period last year, while for Sep 2025 it was $286614.1, marking a year-over-year decrease of 7304.61%. This contributed to the annual value of $657516.6 for FY2024, which is 2718.62% down from last year.
  • AC Immune's Capital Expenditures amounted to -$72504.3 in Q3 2025, which was up 6282.99% from -$450543.1 recorded in Q2 2025.
  • In the past 5 years, AC Immune's Capital Expenditures ranged from a high of $4.9 million in Q4 2021 and a low of -$873786.6 during Q1 2021
  • For the 5-year period, AC Immune's Capital Expenditures averaged around $249323.5, with its median value being -$216232.5 (2023).
  • In the last 5 years, AC Immune's Capital Expenditures soared by 7676.02% in 2022 and then tumbled by 49917.46% in 2025.
  • Over the past 5 years, AC Immune's Capital Expenditures (Quarter) stood at $4.9 million in 2021, then plummeted by 48.71% to $2.5 million in 2022, then tumbled by 36.0% to $1.6 million in 2023, then decreased by 25.12% to $1.2 million in 2024, then tumbled by 105.98% to -$72504.3 in 2025.
  • Its Capital Expenditures stands at -$72504.3 for Q3 2025, versus -$450543.1 for Q2 2025 and -$402634.7 for Q1 2025.